A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Park, Won; Hrycaj, Paweł; Jeka, Sławomir; Kovalenko, Volodymyr; Lysenko, Grygorii; C. Miranda, Pedro; Mikažāne, Helēna; Gutiérrez‐Ureña, Sergio; Jin Lim, Mie; Lee, Yeon-Ah; Joon Lee, Sang; Kim, HoUng; Yoo, Dae‐Hyun; Braun, Jürgen

doi:10.1136/annrheumdis-2012-203091

Public

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Published in Annals of the Rheumatic Diseases • May 18, 2013

Authors:

Won Park

Paweł Hrycaj

Sławomir Jeka

Abstract

OBJECTIVES: To compare the pharmacokinetics (PK), safety and efficacy of innovator infliximab (INX) and CT-P13, a biosimilar to INX, in patients with active ankylosing spondylitis (AS). METHODS: Phase 1 randomised, double-blind, multicentre, multinational, parallel-group study. Patients were randomi...

Subject

Medicine

Ankylosing spondylitis

Pharmacokinetics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!